Dr. Reddy's Laboratories Limited has informed the Exchange that Record date for the purpose of Final Dividend is 10-Jul-2026.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's reported FY26 consolidated revenues of ₹335.9 billion, up 3.2% YoY to ₹325.5 billion. However, profit after tax fell 25% to ₹42.9 billion from ₹57.2 billion, with Q4FY26 severely impacted by a one-time Shelf Stock Adjustment of ₹4.5 billion for Lenalidomide, impairments from discontinued CAR-T programs (₹1.35 billion), and impairment of Eftilagimod Alfa (₹0.91 billion), all in the Global Generics segment. Q4 PAT was only ₹2.2 billion vs ₹15.9 billion in Q4FY25. EBITDA margin compressed to 22.8% from 28.3% in FY25. The Board recommended a final dividend of ₹8 per share (record date July 10, 2026), approved a new statutory auditor (Deloitte Haskins & Sells, LLP), appointed two new Independent Directors, and elevated Sandeep Khandelwal to Senior Management. The SEC and DOJ closed their FCPA investigation with no enforcement action.
The sharp PAT decline and margin compression reflect multiple one-off hits; however, excluding these, underlying business showed resilience in emerging markets and India. The clean audit opinion and resolution of regulatory investigations are positives. Dividend signals continued shareholder returns despite a challenging year.